Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 6NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 2Lymphoma 2Waldenstrom Macroglobulinemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, B-Cell 1Leukemia 1Hodgkin Disease 1Hematologic Diseases 1Ganglioneuroblastoma 1

Interventions

Cyclophosphamide 11Rituximab 6Prednisone 6fludarabine 5Vincristine 5Doxorubicin 5Etoposide 4fludarabine phosphate 3Bortezomib 3Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2Magnetic Resonance Imaging 2MLN 8237 2Electrocardiography 2Echocardiography 2Diphenhydramine 2CT-P10 2Automobiles 2Acetaminophen 2venetoclax 1varlilumab 1tositumomab I-131 1tazemetostat 1saponin QA-21V1 1romidepsin 1pomalidomide 1obinutuzumab 1molibresib 1magrolimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, B-Cell × Leukapheresis × Clear all
NCT01087294 2026-06-01

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
85 enrolled
LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡